MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. (MAIA): 18 pipeline candidates · 18 upcoming catalysts · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
N/A
D/E 0.27 · 0% dilution
Lead: Approved
18 candidates
18 upcoming, next in ~561d
6 buys · 0 sells (180d)
A transparent, data-derived signal for MAIA Biotechnology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$80.3M
Cash
$0
Quarterly Burn
$5.3M
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (18 candidates)
| Drug | Phase |
|---|---|
| 6-thio-2'-deoxyguanosine | Phase 2 |
| angiomax rtu | Approved |
| angiomax rtu | Approved |
| ateganosine | Preclinical |
| baclofen | Approved |
| baclofen | Approved |
| bortezomib | Approved |
| bortezomib | Approved |
| cemiplimab | Phase 2 |
| daptomycin | Approved |
Showing 10 of 18 candidates. Sign up for full pipeline.
Upcoming Catalysts (18)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
28
Total value held
$12.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,148,090 | $5.8M |
| alyeska investment group, l.p. | 2,500,000 | $3.5M |
| 683 capital management, llc | 1,066,666 | $1.5M |
| geode capital management, llc | 360,481 | $505K |
| vanguard fiduciary trust co | 199,314 | $279K |
| state street corp | 138,950 | $195K |
| blackrock, inc. | 127,978 | $179K |
| corsair capital management, l.p. | 100,000 | $140K |
| northern trust corp | 52,539 | $74K |
| ubs group ag | 51,917 | $73K |
Showing top 10 of 28 institutional holders of MAIA Biotechnology, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in MAIA Biotechnology, Inc.'s pipeline?
MAIA Biotechnology, Inc. (MAIA) has 18 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MAIA Biotechnology, Inc.'s lead drug candidate?
MAIA Biotechnology, Inc.'s most advanced tracked candidate is 6-thio-2'-deoxyguanosine (Phase 2) for Carcinoma, Non-Small -Cell Lung; Carcinoma, Non-Small-Cell Lung.
What is MAIA Biotechnology, Inc.'s next catalyst?
MAIA Biotechnology, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs " — expected December 31, 2027.
What is MAIA Biotechnology, Inc.'s market capitalization?
MAIA Biotechnology, Inc.'s market capitalization is approximately $80.3M.
Who is the CEO of MAIA Biotechnology, Inc.?
Dr. Vlad Vitoc M.B.A., M.D. is the chief executive officer of MAIA Biotechnology, Inc. (MAIA).
Get the full picture on MAIA Biotechnology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.